Coherus Oncology Initiates Sale Process for Legacy Biosimilars Assets
1 report, 1 independent
Updated Sep 23
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Coherus Oncology announced it has started the process to market and sell the remaining assets from its former biosimilars business, referred to as the Legacy BioSim Assets. The company retained Oppenheimer & Co. to serve as its financial advisor for this asset sale. The announcement was made on September 23, 2026, and the company also mentioned a special dividend of contingent value rights that was previously announced.
From manilatimes.net
Why it matters
The company stated the process is intended to be robust and have global reach to solicit interest and bids for the asset package. This sale is reportedly for the benefit of the company's shareholders.
From manilatimes.net
Who's involved
- Redwood CityHeadquarters location of Coherus Oncology
Keep exploring
The entities involved
-
Redwood City
city in San Mateo County, California, United States